** Shares in medical device maker Dexcom DXCM.O rose ~7.7% and it was the second biggest gainer in the S&P 500 healthcare index .SPXHC after its quarterly EPS, revenue beat expectations

** The provider of glucose monitors reported quarterly revenue of $1.26 bln vs $1.11 bln year-ago and Street view of $1.246 bln, while on an as-reported basis EPS came in at $0.68 vs Street expectations for $64, as per LSEG

** DXCM forecast FY revenue of $5.16 bln - $5.25 billion, which would be appx 11-13% growth in line with guidance provided last month

** Stock last traded at $70.13 vs median PT of $85, which is up from $84.41 month ago, as per LSEG which shows 31 analyst ratings: 13 'strong buy,' 13 'buy,' 4 'hold,' and 1 'sell'

** YTD the stock is up 5.6%, after falling for the last two years while S&P 500 healthcare index .SPXHC is up ~2% so far this year after rising in the last 3 years. The index was up 1.6% on Friday

(Reporting by Sinead Carew)

((sinead.carew@thomsonreuters.com))